Skip to content

Does Medicare cover Ozempic?

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Medicare Part D can cover Ozempic when it's prescribed for a use Part D covers, and CMS names type 2 diabetes as one. Part D doesn't cover it for weight loss, and Ozempic isn't one of the drugs in the Medicare GLP-1 Bridge. A negotiated Medicare price of $274 for a 30-day supply takes effect on January 1, 2027.

Source: Ozempic FDA label

Key takeaways

  • Part D can cover Ozempic for type 2 diabetes. Ask your plan about its formulary, tier and prior authorization.
  • Part D doesn't cover Ozempic for weight loss, and the Medicare GLP-1 Bridge doesn't include it.
  • Under Part D in 2026, you pay 25% after your deductible until out-of-pocket spending reaches $2,100, then nothing for covered drugs.
  • The $274 negotiated price starts January 1, 2027, but your plan still sets your share.
  • The Ozempic savings card excludes government beneficiaries, so you can't use it with Medicare.

Whether Medicare pays for Ozempic comes down to the reason on the prescription. For a use Part D (Medicare’s drug coverage) covers, such as type 2 diabetes, the route is your Part D plan. For weight loss alone, Part D is barred by law, and the temporary Medicare GLP-1 Bridge doesn’t include Ozempic. This page sits under our Medicare and GLP-1 guide, and the medicine itself is covered on the Ozempic page.

The short version

  • Ozempic for type 2 diabetes: coverable by Part D, through your plan. CMS lists type 2 diabetes as an indication eligible for Part D coverage.
  • Ozempic for weight loss: not covered by Part D, and not available through the Bridge.
  • From January 1, 2027: a negotiated Medicare price of $274 for a 30-day supply applies, and Part D plans must include the drug on their formularies (their lists of covered drugs).

When does Part D cover Ozempic?

CMS’s stated policy is that these medicines are coverable in Part D only when they’re used for a medically accepted indication other than weight loss, and it gives type 2 diabetes as an example. In its Bridge guidance, CMS says: “Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage.”

It adds that a Part D beneficiary with a GLP-1 prescription for an indication covered under Part D should keep getting it through the Part D plan. So if Ozempic is prescribed for your diabetes, ask your plan: is Ozempic on the formulary, which tier is it on, and does it need prior authorization (the plan’s approval before it pays)?

The diagnosis your prescriber is treating decides this. The same pen can be covered for one patient and excluded for another.

Why will Part D not pay for Ozempic for weight loss?

The Part D statute excludes “agents when used for anorexia, weight loss, or weight gain” from the definition of a covered Part D drug. CMS has applied that since Part D began, without separating people who have obesity from people who don’t. Under that policy, a drug used for weight loss is coverable only when it’s being used for another medically accepted indication.

Is Ozempic part of the Medicare GLP-1 Bridge?

No. The Bridge is a CMS demonstration running from July 1, 2026 through December 31, 2027, with a $50 copay for a one-month supply. It covers Foundayo, Wegovy and Zepbound in the KwikPen only. Ozempic isn’t one of its products.

Two Bridge rules matter if you take Ozempic:

  • Type 2 diabetes rules you out. People with type 2 diabetes aren’t eligible for the Bridge, whether or not their Part D plan covers a GLP-1 for it.
  • A Part D fill rules you out. If your Part D plan has paid for a GLP-1 in 2026, for any reason, you’re not eligible, and CMS names Ozempic among the drugs it checks for. A GLP-1 paid for outside Part D, with cash or other insurance, isn’t what this exclusion describes.

The Bridge explainer has every rule, the eligibility checker runs through them, and Does Medicare cover Wegovy? covers the semaglutide product the Bridge does include.

One more program carries Ozempic’s name. CMS lists all formulations of Ozempic among the drugs in its BALANCE Model, for covered indications and for weight management. But CMS’s own page refers to BALANCE not launching in Medicare in 2027, so it doesn’t change what Medicare enrollees pay for Ozempic in 2027. See the BALANCE Model page.

What do you pay for Ozempic under Part D?

Your plan sets the amount, inside limits that apply to every plan in 2026:

  • Deductible (what you pay before your plan starts sharing the cost): no Medicare drug plan may have a deductible above $615, and some have none.
  • After the deductible: you pay 25% of the cost as coinsurance for brand-name drugs.
  • The cap: once your out-of-pocket spending on covered Part D drugs reaches $2,100, you pay nothing for covered Part D drugs for the rest of the calendar year.

Two programs can ease the timing or the amount. The Medicare Prescription Payment Plan spreads your out-of-pocket costs for plan-covered drugs across the calendar year. Every plan offers it and joining costs nothing, but it doesn’t lower what you owe. Extra Help is a Medicare program for people with limited income and resources that helps pay Part D premiums, deductibles and coinsurance. The Part D costs page works through both.

What changes for Ozempic in 2027?

Semaglutide, sold as Ozempic, Rybelsus and Wegovy, has a negotiated Medicare price that takes effect on January 1, 2027: $274 for a 30-day supply. CMS sets that against a 2024 list price of $959, a 71% discount. For one Ozempic 4 mg/3 mL pen, the maximum fair price is $276.78 per package.

By law, Part D plans, including Medicare Advantage drug plans, must include the selected drugs on their formularies.

Two cautions. The negotiated price is a price for the drug within Part D, not a copay. Your plan still sets your share, within the 2027 limits of a deductible no higher than $700 and a $2,400 out-of-pocket cap. And it applies to Part D covered uses. It doesn’t lift the weight-loss exclusion.

What if Medicare will not pay for Ozempic?

Then the manufacturer’s savings card won’t help. The Ozempic savings card brings the cost to as little as $25 for people whose commercial insurance covers Ozempic, but it excludes government beneficiaries.

That leaves paying cash. Novo Nordisk’s list price is $1,027.51 per pen. Its self-pay offer is $349 a month for the 0.25 mg, 0.5 mg or 1 mg pen and $499 for the 2 mg pen, with a limited-time price of $199 for the first two monthly fills of the two lowest doses for new patients. No insurance is used, and eligibility and restrictions apply. Check those terms before you rely on a price, because the TrumpRx listing of the same prices says government beneficiaries are excluded.

The Ozempic cost page lists every price. If you also have Medicaid, its rules are separate and set state by state: see Medicaid coverage of GLP-1 medicines.

What to ask, and whom

  • Your prescriber: what is Ozempic being prescribed for? That answer decides whether Part D can cover it.
  • Your Part D plan: is Ozempic on the formulary, which tier is it on, and is prior authorization needed?
  • Your pharmacy: what will this fill cost me today, and how much of my deductible is left?
  • Medicare: if you’re not sure what type of plan you have, call 1-800-MEDICARE (1-800-633-4227).

Frequently asked questions

Does Medicare cover Ozempic for weight loss?

No. The Part D statute excludes agents when used for weight loss, and CMS applies that whether or not you have obesity. The Medicare GLP-1 Bridge, which does cover weight management, includes Foundayo, Wegovy and the Zepbound KwikPen. Ozempic isn't on that list, so there's no Medicare route to Ozempic for weight loss alone.

Does Medicare cover Ozempic for type 2 diabetes?

Part D can. CMS lists type 2 diabetes as an indication (a use) eligible for Part D coverage. It says people with a GLP-1 prescription for a Part D covered indication should get it through their Part D plan. Check with your plan whether Ozempic is on its formulary, the plan's list of covered drugs, and on which tier.

How much is Ozempic with Medicare Part D?

It depends on your plan. In 2026, no Part D plan may have a deductible above $615. After the deductible, you pay 25% coinsurance until your out-of-pocket spending on covered Part D drugs reaches $2,100, and then you pay nothing for covered drugs for the rest of the calendar year.

What is the Medicare negotiated price for Ozempic in 2027?

CMS and Novo Nordisk agreed a negotiated price of $274 for a 30-day supply of semaglutide, which covers Ozempic, Rybelsus and Wegovy, against a 2024 list price of $959. For one Ozempic 4 mg/3 mL pen, the maximum fair price is $276.78 per package. The prices take effect on January 1, 2027.

Can I use the Ozempic savings card with Medicare?

No. The Ozempic savings card lowers the cost to as little as $25 for people with commercial insurance that covers Ozempic, but it excludes government beneficiaries. That includes people on Medicare. The TrumpRx listing of Ozempic self-pay prices also excludes government beneficiaries.

Sources (15)

  1. 1.
    Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
    “The statutory definition of a covered Part D drug at section 1860D-2(e)(2) of the Social Security Act (the Act) excludes certain drugs and uses—specifically, those that may be excluded by Medicaid under section 1927(d)(2) of the Act. This includes, at section 1927(d)(2)(A) of the Act, “agents when used for anorexia, weight loss, or weight gain.” Historically, drugs used for weight loss have been excluded from the definition of covered Part D drug, regardless of their use for treatment of individuals with obesity, and have been an optional drug benefit for Medicaid programs.”
  2. 2.
    CMS: Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (CMS-4208-P)
    “Since the inception of the Part D program, CMS has interpreted the statutory exclusion of “agents when used for weight loss” to mean that a drug, when used for weight loss, is excluded from the definition of a covered Part D drug. This historical interpretation does not distinguish between use of a drug for treatment of individuals with obesity and individuals without obesity. Therefore, under current policy, anti-obesity medications are only coverable in Part D if the drug is being used to treat another condition that is a medically accepted indication other than weight loss or weight management (for example, type 2 diabetes or to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight).”
  3. 3.
    CMS: Information for Part D Plans
    “Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. [...] If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
  4. 4.
    CMS: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027
    “Below is the list of negotiated prices, which the statute refers to as maximum fair prices (MFPs), for the 15 selected drugs covered under Medicare Part D that will go into effect beginning January 1, 2027, based on negotiations and agreements reached between CMS and participating drug companies. [table] Drug Name: Ozempic; Rybelsus; Wegovy. Participating Drug Company: Novo Nordisk Inc. Agreed to Negotiated Price for 30-day Supply for CY 2027: $274. List Price for 30-day Supply, CY 2024: $959. Discount of Negotiated Price from 2024 List Price: 71%.”
  5. 5.
    CMS: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027
    “For example, for the selected drug with the highest total gross covered prescription drug costs under Part D in 2024, Ozempic; Rybelsus; Wegovy, the MFP applied across three commonly used dosage forms and strengths will be: [table] NDC-11: 00169-4130-13. Description of package: 4mg/3mL Pen, 1 Pen (Ozempic). MFP per package: $276.78.”
  6. 6.
    CMS: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027
    “These negotiated prices will become effective on January 1, 2027. [...] As required by law, Medicare prescription drug plans, including standalone Part D plans and Medicare Advantage-prescription drug plans, must include in their formularies the selected drugs for which CMS and the participating drug company have agreed to a negotiated price.”
  7. 7.
    Medicare.gov: How much does Medicare drug coverage cost?
    “After you reach your full deductible (if your plan has a deductible), you’ll pay 25% of the cost as coinsurance for your generic and brand-name drugs until your out-of-pocket spending on covered Part D drugs reaches $2,100 in 2026 ($2,400 in 2027)(including certain payments made on your behalf, like through the Extra Help program). Then, you’ll automatically get “catastrophic coverage.” Catastrophic coverage stage: You won’t have to pay out-of-pocket for covered Part D drugs for the rest of the calendar year.”
  8. 8.
    Medicare.gov: How much does Medicare drug coverage cost?
    “No Medicare drug plan may have a deductible more than $615 in 2026 ($700 in 2027). Some Medicare drug plans don’t have a deductible.”
  9. 9.
    Medicare.gov: What’s the Medicare Prescription Payment Plan?
    “The Medicare Prescription Payment Plan is a payment option that works with your current drug coverage to help you manage your out-of-pocket costs for drugs covered by your plan by spreading them across the calendar year (January–December). [...] All plans offer this payment option, and participation is voluntary. [...] There’s no cost to participate in the Medicare Prescription Payment Plan. [...] This payment option might help you manage your monthly expenses, but it doesn’t save you money or lower your drug costs.”
  10. 10.
    Medicare.gov: Help with drug costs
    “"Extra Help" is a Medicare program to help people with limited income and resources pay Medicare drug coverage (Part D) premiums, deductibles, coinsurance, and other costs. [...] Income and resource limits in 2026: [table] Individual: Income limit $23,940, Resource limit $18,090. Married couple: Income limit $32,460, Resource limit $36,100.”
  11. 11.
    CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
    “All formulations of Mounjaro®, Ozempic®, Rybelsus®, and Wegovy®, the KwikPen formulation of Zepbound®, and Foundayo™. These are included for both currently covered indications (ex: type 2 diabetes) as well as weight management indications.”
  12. 12.
    CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
    “Will the Medicare GLP-1 Bridge continue into 2027? Yes. The Medicare GLP-1 Bridge has been extended through December 31, 2027. [...] What is the impact of the BALANCE Model not launching in Medicare in 2027 on the Medicare GLP-1 Bridge? The Medicare GLP-1 Bridge will be extended through December 31, 2027, providing eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs and allowing CMS to collect additional data on GLP-1 utilization to share with Part D plan sponsors ahead of potential implementation of BALANCE in Part D.”
  13. 13.
  14. 14.
  15. 15.